ClinicalTrials.gg
CompletedNCT02260193Updated Jul 1, 2022Results posted

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

A Phase 2 interventional study of AKB-6548 and AKB-6548 in Anemia and End Stage Renal Disease, sponsored by Akebia Therapeutics. Completed at 16 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
12th of 27
94 · median 60
Started
2014
with 2 others
Phase 2
8 of 27
none open now
Registered
5th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 12th largest by enrollment, is one of 3 that started in 2014, is one of 8 in phase 2, and was the 5th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with end stage renal disease undergoing chronic hemodialysis.

03

Conditions studied

  • Anemia
  • End Stage Renal Disease

Keywords

  • anemia
  • end stage renal disease
  • chronic kidney disease
  • CKD
  • dialysis
  • chronic renal insufficiency
  • renal impairment
  • erythropoietin
  • kidney
  • oral anemia treatment
  • hemoglobin
  • hypoxia-inducible factor
  • HIF
  • hypoxia-inducible factor propyl-hydroxylase inhibitor
  • HIF-PHI
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • 18 to 79 years inclusive
  • Chronic Kidney Disease (CKD) Stage 5 on chronic hemodialysis for at least 3 months
  • Anemia secondary to CKD treated with erythropoiesis stimulating agent and intravenous iron

Key Exclusion Criteria:

  • >44.0 kilograms per meter squared (kg/m\^2)
  • Transfusion within 8 weeks prior to Screening
  • or total >1.25x
  • Uncontrolled hypertension
  • Class III or IV congestive heart failure
  • Myocardial infarction, acute coronary syndrome, stroke or within 6 months prior to Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    AKB-6548, starting dose 1

    Drug: AKB-6548

  • Experimental
    AKB-6548, starting dose 2

    Drug: AKB-6548

  • Experimental
    AKB-6548, starting dose 3

    Drug: AKB-6548

Interventions

  • Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

  • Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

  • Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.

06

What researchers measure

Primary outcomes

  1. Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average

    Change from pre-dose average was calculated by the mid-study average minus the pre-dose average. The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits.

    Time frame: Pre-dose (Screening, Second Screening, and Baseline), Week 7, and Week 8

  2. Change From Pre-dose Average in Hgb Level to The End-of-study Average

    Change from pre-dose average was calculated by the end-of-study average minus the pre-dose average. The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.

    Time frame: Pre-dose, Week 15, and Week 16

  3. Change From Mid-study Average in Hgb Level to The End-of-study Average

    Change from mid-study average was calculated by the end-of-study average minus the mid-study average. The mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.

    Time frame: Week 7, Week 8, Week 15, and Week 16

Secondary outcomes

  1. Change From Baseline in Hgb

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hgb was defined as the average of the three samples obtained prior to dosing.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16

  2. Change From Baseline in Hematocrit

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hematocrit was defined as the last observation before the first dose of study medication.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16

  3. Change From Baseline in Red Blood Cell (RBC) Count

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline RBC Count was defined as the average of the three samples obtained prior to dosing.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16

  4. Change From Baseline in Absolute Reticulocyte Count

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline absolute reticulocyte count was defined as the last observation before the first dose of study medication.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16

  5. Change From Baseline in Percent Reticulocyte Count

    Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100. Baseline percent reticulocyte count was defined as the last observation before the first dose of study medication.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16

  6. Change From Baseline in Reticulocyte Hgb Content

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline reticulocyte Hgb content was defined as the average of the three samples obtained prior to dosing.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 16

  7. Change From Baseline in Ferritin

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline ferritin was defined as the last observation before the first dose of study medication.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16

  8. Change From Baseline in Hepcidin

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline hepcidin was defined as the last observation before the first dose of study medication.

    Time frame: Baseline, Week 8, and Week 16

  9. Change From Baseline in Total Iron-Binding Capacity (TIBC)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline TIBC was defined as the last observation before the first dose of study medication.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16

  10. Change From Baseline in Transferrin Saturation (TSAT)

    Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100. Baseline TSAT was defined as the last observation before the first dose of study medication.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16

  11. Change From Baseline in Iron

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline iron was defined as the last observation before the first dose of study medication.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16

  12. Number of Participants Who Received Erythropoiesis-stimulating Agent (ESA) Rescue Therapy

    ESA rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.

    Time frame: Up to Week 16

  13. Number of Participants Who Received Blood Transfusion Rescue Therapy

    Blood transfusion rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.

    Time frame: Up to Week 16

  14. Mean Plasma Concentrations of Vadadustat

    Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.

    Time frame: Pre-dialysis and post-dialysis on Week 2 and Week 16

  15. Mean Plasma Concentrations of Vadadustat-O-Glucuronide Metabolite

    Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.

    Time frame: Pre-dialysis and post-dialysis on Week 2 and Week 16

  16. Mean Plasma Concentrations of Vadadustat-Acyl-Glucuronide Metabolite

    Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.

    Time frame: Pre-dialysis and post-dialysis on Week 2 and Week 16

  17. Number of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. A TEAE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. A SAE included AEs that met one or more of the following criteria/outcomes: death, lifethreatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, and congenital anomaly/birth defect.

    Time frame: Up to Week 20

  18. Number of Participants With Clinically Significant Changes From Baseline in Vital Signs

    Parameters assessed for vital signs included sitting blood pressure, pulse, respiratory rate, and body temperature. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to Week 20

  19. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

    Parameters assessed for laboratory values included hematology, serum chemistry, urinalysis, iron indices, C-reactive protein, lipid profile, biomarkers, and pregnancy tests. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to Week 20

  20. Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings

    A standard 12-lead ECG was performed following dosing in a supine position for approximately 5 minutes. ECGs were taken prior to vital sign assessments, circulatory access cannulation, and blood draws when possible. Clinical significance was determined by the investigator.

    Time frame: Up to Week 20

Other outcomes

  1. Mean Intravenous Iron Replacement Therapy

    Intravenous iron was administered throughout the study to maintain ferritin levels in the range of ≥100 ng/mL to ≤1200 ng/mL.

    Time frame: Baseline, Week 8, and Week 16

07

Results

Posted Jul 1, 2022

Participant flow

Participant flow — Overall Study
MilestoneVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Started303331
Completed242421
Not completed6910
Withdrew: Lack of efficacy016
Withdrew: Adverse event341
Withdrew: Protocol violation040
Withdrew: Withdrawal by subject302
Withdrew: Kidney transplantation001

Outcome measures

PrimaryChange From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average

Change from pre-dose average was calculated by the mid-study average minus the pre-dose average. The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits.

Time frame:
Pre-dose (Screening, Second Screening, and Baseline), Week 7, and Week 8
Reported as:
Mean · Grams per deciliter (g/dL)
Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average
Grams per deciliter (g/dL)Vadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Pre-dose Average10.43 ± 0.64510.55 ± 0.57710.52 ± 0.534
Change from pre-dose average to the mid-study average0.00 ± 0.897-0.29 ± 0.970-0.36 ± 1.134
Statistical analysis
  • Vadadustat 300 mg Once Daily (QD) vs Vadadustat 450 mg QD · Least squares mean differences: 0.29 · 95% CI -0.25 to 0.82
  • Vadadustat 300 mg Once Daily (QD) vs Vadadustat 450 mg 3 Times Per Week (TIW) · Least squares mean differences: 0.36 · 95% CI -0.19 to 0.90
  • Vadadustat 450 mg QD vs Vadadustat 450 mg 3 Times Per Week (TIW) · Least squares mean differences: 0.07 · 95% CI -0.48 to 0.61
PrimaryChange From Pre-dose Average in Hgb Level to The End-of-study Average

Change from pre-dose average was calculated by the end-of-study average minus the pre-dose average. The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.

Time frame:
Pre-dose, Week 15, and Week 16
Reported as:
Mean · g/dL
Change From Pre-dose Average in Hgb Level to The End-of-study Average
g/dLVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Pre-dose Average10.43 ± 0.64510.55 ± 0.57710.52 ± 0.534
Change From Pre-dose average to The End-of-study Average-0.03 ± 0.902-0.07 ± 0.973-0.14 ± 1.123
Statistical analysis
  • Vadadustat 300 mg Once Daily (QD) vs Vadadustat 450 mg QD · Least squares mean differences: 0.04 · 95% CI -0.54 to 0.61
  • Vadadustat 300 mg Once Daily (QD) vs Vadadustat 450 mg 3 Times Per Week (TIW) · Least squares mean differences: 0.10 · 95% CI -0.49 to 0.70
  • Vadadustat 450 mg QD vs Vadadustat 450 mg 3 Times Per Week (TIW) · Least squares mean difference: 0.07 · 95% CI -0.53 to 0.66
PrimaryChange From Mid-study Average in Hgb Level to The End-of-study Average

Change from mid-study average was calculated by the end-of-study average minus the mid-study average. The mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.

Time frame:
Week 7, Week 8, Week 15, and Week 16
Reported as:
Mean · g/dL
Change From Mid-study Average in Hgb Level to The End-of-study Average
g/dLVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Mid-study Average10.41 ± 0.83410.26 ± 1.16710.19 ± 0.950
Change From Mid-study Average to The End-of-study Average-0.18 ± 0.5120.16 ± 0.809-0.07 ± 0.611
Statistical analysis
  • Vadadustat 300 mg Once Daily (QD) vs Vadadustat 450 mg QD · Least squares mean difference: -0.34 · 95% CI -0.71 to 0.04
  • Vadadustat 300 mg Once Daily (QD) vs Vadadustat 450 mg 3 Times Per Week (TIW) · Least squares mean difference: -0.11 · 95% CI -0.50 to 0.29
  • Vadadustat 450 mg QD vs Vadadustat 450 mg 3 Times Per Week (TIW) · Least squares mean difference: 0.23 · 95% CI -0.16 to 0.62
SecondaryChange From Baseline in Hgb

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hgb was defined as the average of the three samples obtained prior to dosing.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 16
Reported as:
Mean · g/dL
Change From Baseline in Hgb
g/dLVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline10.50 ± 0.70210.51 ± 0.75510.50 ± 0.646
Change from Baseline to Week 4-0.06 ± 0.708-0.21 ± 0.814-0.35 ± 0.887
Change from Baseline to Week 8-0.14 ± 1.058-0.39 ± 1.201-0.37 ± 1.386
Change from Baseline to Week 120.02 ± 0.995-0.11 ± 1.087-0.06 ± 1.210
Change from Baseline to Week 16-0.03 ± 0.946-0.13 ± 1.076-0.06 ± 1.146
SecondaryChange From Baseline in Hematocrit

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hematocrit was defined as the last observation before the first dose of study medication.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 16
Reported as:
Mean · Percentage of red blood cells in blood
Change From Baseline in Hematocrit
Percentage of red blood cells in bloodVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline31.2 ± 2.5831.6 ± 3.7531.4 ± 2.75
Change from Baseline to Week 4-0.4 ± 2.82-1.4 ± 3.36-0.7 ± 3.14
Change from Baseline to Week 8-1.0 ± 3.87-1.6 ± 4.73-1.7 ± 4.43
Change from Baseline to Week 12-0.2 ± 3.35-0.8 ± 4.07-0.1 ± 4.35
Change from Baseline to Week 16-0.8 ± 3.26-1.2 ± 4.19-0.2 ± 3.67
SecondaryChange From Baseline in Red Blood Cell (RBC) Count

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline RBC Count was defined as the average of the three samples obtained prior to dosing.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 16
Reported as:
Mean · 10^6 cells per microliter
Change From Baseline in Red Blood Cell (RBC) Count
10^6 cells per microliterVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline3.34 ± 0.2783.49 ± 0.4463.49 ± 0.385
Change from Baseline to Week 4-0.06 ± 0.235-0.11 ± 0.346-0.16 ± 0.276
Change from Baseline to Week 8-0.09 ± 0.357-0.19 ± 0.482-0.16 ± 0.432
Change from Baseline to Week 12-0.01 ± 0.325-0.14 ± 0.473-0.10 ± 0.464
Change from Baseline to Week 16-0.05 ± 0.309-0.17 ± 0.453-0.08 ± 0.412
SecondaryChange From Baseline in Absolute Reticulocyte Count

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline absolute reticulocyte count was defined as the last observation before the first dose of study medication.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 16
Reported as:
Mean · 10^6 cells per microliter
Change From Baseline in Absolute Reticulocyte Count
10^6 cells per microliterVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline0.0704 ± 0.025480.0661 ± 0.023000.0742 ± 0.02777
Change from Baseline to Week 4-0.0059 ± 0.021660.0023 ± 0.02597-0.0001 ± 0.02813
Change from Baseline to Week 8-0.0054 ± 0.017940.0041 ± 0.02492-0.0018 ± 0.02571
Change from Baseline to Week 120.0001 ± 0.015920.0133 ± 0.027340.0033 ± 0.02479
Change from Baseline to Week 16-0.0009 ± 0.022510.0048 ± 0.024090.0040 ± 0.02470
SecondaryChange From Baseline in Percent Reticulocyte Count

Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100. Baseline percent reticulocyte count was defined as the last observation before the first dose of study medication.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 16
Reported as:
Mean · Percent change
Change From Baseline in Percent Reticulocyte Count
Percent changeVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline2.14 ± 0.8021.89 ± 0.5722.19 ± 0.927
Change from Baseline to Week 4-0.16 ± 0.5780.14 ± 0.7870.07 ± 0.884
Change from Baseline to Week 8-0.15 ± 0.5390.24 ± 0.6490.03 ± 0.710
Change from Baseline to Week 12-0.04 ± 0.4880.48 ± 0.7040.17 ± 0.835
Change from Baseline to Week 16-0.01 ± 0.5860.23 ± 0.7010.15 ± 0.817
SecondaryChange From Baseline in Reticulocyte Hgb Content

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline reticulocyte Hgb content was defined as the average of the three samples obtained prior to dosing.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 16
Reported as:
Mean · μg/dL
Change From Baseline in Reticulocyte Hgb Content
μg/dLVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline32.39 ± 1.79932.12 ± 1.67530.99 ± 2.372
Change from Baseline to Week 2-0.13 ± 1.302-0.03 ± 0.9721.01 ± 1.621
Change from Baseline to Week 4-0.07 ± 0.859-0.21 ± 1.0231.02 ± 1.425
Change from Baseline to Week 80.41 ± 1.159-0.27 ± 1.3081.13 ± 1.301
Change from Baseline to Week 160.15 ± 1.0260.58 ± 1.284-0.18 ± 1.494
SecondaryChange From Baseline in Ferritin

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline ferritin was defined as the last observation before the first dose of study medication.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 16
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Change From Baseline in Ferritin
Nanograms per milliliter (ng/mL)Vadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline762.88 ± 470.462781.96 ± 465.148807.75 ± 430.981
Change from Baseline to Week 4-48.80 ± 205.733-61.21 ± 217.068-10.29 ± 254.574
Change from Baseline to Week 846.85 ± 529.361-99.11 ± 240.436-48.71 ± 289.063
Change from Baseline to Week 12-15.70 ± 316.387-61.81 ± 302.7190.92 ± 342.188
Change from Baseline to Week 16-56.67 ± 317.098-115.36 ± 276.640-39.03 ± 484.937
SecondaryChange From Baseline in Hepcidin

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline hepcidin was defined as the last observation before the first dose of study medication.

Time frame:
Baseline, Week 8, and Week 16
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Change From Baseline in Hepcidin
Nanograms per milliliter (ng/mL)Vadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline102.59 ± 58.938119.61 ± 54.766105.35 ± 46.805
Change from Baseline to Week 8-6.46 ± 49.002-27.80 ± 56.752-9.14 ± 46.498
Change from Baseline to Week 16-15.11 ± 46.526-21.66 ± 45.381-4.87 ± 50.379
SecondaryChange From Baseline in Total Iron-Binding Capacity (TIBC)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline TIBC was defined as the last observation before the first dose of study medication.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 16
Reported as:
Mean · Micrograms per deciliter (μg/mL)
Change From Baseline in Total Iron-Binding Capacity (TIBC)
Micrograms per deciliter (μg/mL)Vadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline204.5 ± 39.72196.7 ± 29.42188.8 ± 32.28
Change from Baseline to Week 425.7 ± 21.9522.0 ± 32.1818.7 ± 22.39
Change from Baseline to Week 823.4 ± 28.1330.3 ± 28.3022.0 ± 25.37
Change from Baseline to Week 1230.6 ± 30.0534.8 ± 28.6923.9 ± 19.62
Change from Baseline to Week 1627.7 ± 35.2724.9 ± 29.1025.7 ± 21.78
SecondaryChange From Baseline in Transferrin Saturation (TSAT)

Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100. Baseline TSAT was defined as the last observation before the first dose of study medication.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 16
Reported as:
Mean · Percent change
Change From Baseline in Transferrin Saturation (TSAT)
Percent changeVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline34.6 ± 11.6333.7 ± 11.1437.5 ± 13.27
Change from Baseline to Week 45.4 ± 15.492.1 ± 16.973.6 ± 15.84
Change from Baseline to Week 82.9 ± 15.921.2 ± 17.313.3 ± 14.87
Change from Baseline to Week 129.1 ± 19.711.3 ± 17.183.7 ± 14.08
Change from Baseline to Week 162.5 ± 14.861.7 ± 17.442.5 ± 13.75
SecondaryChange From Baseline in Iron

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline iron was defined as the last observation before the first dose of study medication.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 16
Reported as:
Mean · μg/dL
Change From Baseline in Iron
μg/dLVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Baseline70.6 ± 26.2566.6 ± 23.7475.4 ± 32.31
Change from Baseline to Week 420.7 ± 32.4718.5 ± 40.9113.3 ± 30.06
Change from Baseline to Week 814.3 ± 33.3811.6 ± 39.1015.0 ± 30.22
Change from Baseline to Week 1231.7 ± 46.7310.8 ± 31.4415.5 ± 28.01
Change from Baseline to Week 1614.0 ± 34.4310.3 ± 37.1614.0 ± 28.62
SecondaryNumber of Participants Who Received Erythropoiesis-stimulating Agent (ESA) Rescue Therapy

ESA rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Received Erythropoiesis-stimulating Agent (ESA) Rescue Therapy
ParticipantsVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Number of Participants Who Received Erythropoiesis-stimulating Agent (ESA) Rescue Therapy462
SecondaryNumber of Participants Who Received Blood Transfusion Rescue Therapy

Blood transfusion rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Received Blood Transfusion Rescue Therapy
ParticipantsVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Number of Participants Who Received Blood Transfusion Rescue Therapy110
SecondaryMean Plasma Concentrations of Vadadustat

Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.

Time frame:
Pre-dialysis and post-dialysis on Week 2 and Week 16
Reported as:
Mean · μg/mL
Mean Plasma Concentrations of Vadadustat
μg/mLVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Week 2 pre-dialysis12.89 ± 13.87617.27 ± 12.7415.329 ± 5.0281
Week 2 post-dialysis13.72 ± 13.72818.69 ± 15.6015.287 ± 5.2117
Week 16 pre-dialysis11.41 ± 8.771615.98 ± 12.0594.813 ± 3.6094
Week 16 post-dialysis13.85 ± 11.92117.38 ± 12.5163.998 ± 2.9709
SecondaryMean Plasma Concentrations of Vadadustat-O-Glucuronide Metabolite

Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.

Time frame:
Pre-dialysis and post-dialysis on Week 2 and Week 16
Reported as:
Mean · μg/mL
Mean Plasma Concentrations of Vadadustat-O-Glucuronide Metabolite
μg/mLVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Week 2 pre-dialysis16.66 ± 13.50826.36 ± 21.1116.295 ± 4.8326
Week 2 post-dialysis8.725 ± 7.678613.26 ± 13.1543.101 ± 2.2190
Week 16 pre-dialysis15.74 ± 14.35617.19 ± 13.2667.843 ± 8.0807
Week 16 post-dialysis7.833 ± 5.54388.408 ± 6.43612.998 ± 2.5811
SecondaryMean Plasma Concentrations of Vadadustat-Acyl-Glucuronide Metabolite

Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.

Time frame:
Pre-dialysis and post-dialysis on Week 2 and Week 16
Reported as:
Mean · μg/mL
Mean Plasma Concentrations of Vadadustat-Acyl-Glucuronide Metabolite
μg/mLVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Week 2 pre-dialysis0.0136 ± 0.006110.0224 ± 0.018890.0800 ± NA
Week 2 post-dialysis0.0142 ± 0.010160.0095 ± 0.00246—
Week 16 pre-dialysis0.0129 ± 0.010830.0210 ± 0.00700—
Week 16 post-dialysis0.0100 ± 0.006030.0087 ± 0.00351—
SecondaryNumber of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. A TEAE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. A SAE included AEs that met one or more of the following criteria/outcomes: death, lifethreatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, and congenital anomaly/birth defect.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
TEAEs262626
SAEs265
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Vital Signs

Parameters assessed for vital signs included sitting blood pressure, pulse, respiratory rate, and body temperature. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
ParticipantsVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs000
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

Parameters assessed for laboratory values included hematology, serum chemistry, urinalysis, iron indices, C-reactive protein, lipid profile, biomarkers, and pregnancy tests. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
ParticipantsVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values000
SecondaryNumber of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings

A standard 12-lead ECG was performed following dosing in a supine position for approximately 5 minutes. ECGs were taken prior to vital sign assessments, circulatory access cannulation, and blood draws when possible. Clinical significance was determined by the investigator.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings
ParticipantsVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings000
Other pre-specifiedMean Intravenous Iron Replacement Therapy

Intravenous iron was administered throughout the study to maintain ferritin levels in the range of ≥100 ng/mL to ≤1200 ng/mL.

Time frame:
Baseline, Week 8, and Week 16

Results for this outcome have not been posted.

Adverse events

Collected over Up to Week 20 (from the time of the first dose of study medication to last dose + 4 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vadadustat 300 mg Once Daily (QD)0/30 (0%)5/30 (16.7%)22/30 (73.3%)
Vadadustat 450 mg QD0/33 (0%)9/33 (27.3%)19/33 (57.6%)
Vadadustat 450 mg 3 Times Per Week (TIW)0/31 (0%)8/31 (25.8%)23/31 (74.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
Acute myocardial infarctionCardiac disorders1/301/330/31
PneumoniaInfections and infestations1/301/331/31
Arthritis bacterialInfections and infestations1/300/330/31
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications1/300/331/31
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/300/330/31
Cardiac failure congestiveCardiac disorders0/300/331/31
DiarrhoeaGastrointestinal disorders0/300/331/31
Arteriovenous fistula site infectionInfections and infestations0/300/331/31
Diabetes mellitusMetabolism and nutrition disorders0/300/331/31
Fluid overloadMetabolism and nutrition disorders0/300/331/31
Most frequent other events
Showing 10 of 35
Most frequent other events
EventVadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)
DiarrhoeaGastrointestinal disorders4/304/332/31
NauseaGastrointestinal disorders4/303/334/31
Abdominal painGastrointestinal disorders2/304/330/31
VomitingGastrointestinal disorders3/303/333/31
Arteriovenous fistula site complicationInjury, poisoning and procedural complications3/300/330/31
Muscle spasmsMusculoskeletal and connective tissue disorders3/302/331/31
HeadacheNervous system disorders3/302/333/31
CoughRespiratory, thoracic and mediastinal disorders3/300/330/31
Hyperparathyroidism secondaryEndocrine disorders0/300/333/31
HypokalaemiaMetabolism and nutrition disorders0/300/333/31

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Vadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)Total
Mean55.5 ± 12.4459.4 ± 11.6257.8 ± 8.2657.6 ± 10.93
Sex: Female, Male
Sex: Female, Male(Participants)Vadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)Total
Female13151240
Male17181954
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)Total
Hispanic or Latino14181547
Not Hispanic or Latino16151647
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vadadustat 300 mg Once Daily (QD)Vadadustat 450 mg QDVadadustat 450 mg 3 Times Per Week (TIW)Total
American Indian or Alaska Native0011
Asian0123
Native Hawaiian or Other Pacific Islander0202
Black or African American69924
White24211964
More than one race0000
Unknown or Not Reported0000
08

Study locations

16 sites
  • El Granada, California, United States
  • Long Beach, California, United States
  • San Dimas, California, United States
  • Santa Clarita, California, United States
  • Whittier, California, United States
  • Arvada, Colorado, United States
  • Westminster, Colorado, United States
  • Naples, Florida, United States
  • North Miami Beach, Florida, United States
  • Augusta, Georgia, United States
  • Astoria, New York, United States
  • Arlington, Texas, United States
  • Grand Prairie, Texas, United States
  • Greenville, Texas, United States
  • Houston, Texas, United States
  • Mechanicsville, Virginia, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Jul 2015, 10 months.

Results were first posted in Jul 2022, 6 years 11 months after primary completion. A results delay was requested in Oct 2015.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 10 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Oct 9, 2014
StartActual
Sep 10, 2014
Primary completionActual
Jul 22, 2015
CompletionActual
Jul 22, 2015
Results delay requested
Oct 23, 2015
Results first posted
Jul 1, 2022
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02260193
Responsible party
Sponsor
First posted
Oct 9, 2014
Start date
Sep 10, 2014
Primary completion
Jul 22, 2015
Completion
Jul 22, 2015
Results posted
Jul 1, 2022
Last update
Jul 1, 2022

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion